Literature DB >> 22938082

Clinical features and treatment of World Health Organization grade II and III meningiomas in childhood: report of 23 cases.

Xiao-Qiang Wang1, Cheng-Chuan Jiang, Lin Zhao, Ye Gong, Jie Hu, Hong Chen.   

Abstract

OBJECT: High-grade meningiomas in childhood are rare, and their clinical features are unknown. The objective of this study was to determine the clinical characteristics and prognosis of childhood high-grade meningiomas.
METHODS: Twenty-three patients with childhood high-grade meningiomas were treated at the Huashan Hospital. Clinical data were collected, tumor samples were reexamined, and prognoses were attained through follow-up visits and telephone interviews. Survival probability was calculated using the Kaplan-Meier method. A 2-sided probability level of 0.05 was chosen for statistical significance.
RESULTS: The series included 18 males and 5 females (mean age 12.1 years). The most common symptoms were headache and vomiting (43%). Three patients had accompanying neurofibromatosis type II (NF2). The high-grade meningioma cases with NF2 had larger tumor diameters than those without NF2 (p = 0.010). The skull base was the most common tumor site (39%). Complete resections were achieved in 11 patients after their initial operations. Adjuvant radiation therapy was performed in 9 cases. Follow-up evaluations were performed for 20 patients (mean follow-up 70 months). Ten patients experienced recurrences, 2 patients had lung metastases, and 7 patients died of the recurrence. The extent of surgery was significantly related to progression-free survival (PFS; p = 0.038). A negative progesterone receptor combined with strongly positive Bcl-2 immunoreactivity was significantly related to PFS (p = 0.001) and overall survival (p = 0.002). The MIB-1 labeling index was significantly related to overall survival (p = 0.018), whereas postoperative radiation therapy was not significantly related to PFS (p = 0.087) and overall survival (p = 0.40).
CONCLUSIONS: Childhood high-grade meningioma is a rare tumor type. Childhood high-grade meningioma has a male predominance and the basilar region is the most common tumor location. Patients with these tumors have high recurrence and mortality rates. The extent of resection is an important prognosis factor. A negative progesterone receptor combined with a strongly positive Bcl-2 immunoreaction might predict cancer recurrence. The MIB-1 labeling index correlates with the prognosis, and an MIB-1 labeling index > 3% increases the risk of recurrence in childhood high-grade meningioma. More cases should be collected, and longer follow-up periods should be obtained, to evaluate the effects of postoperative radiation therapy in childhood high-grade meningioma.

Entities:  

Mesh:

Year:  2012        PMID: 22938082     DOI: 10.3171/2012.7.PEDS12179

Source DB:  PubMed          Journal:  J Neurosurg Pediatr        ISSN: 1933-0707            Impact factor:   2.375


  5 in total

1.  Papillary meningioma of the central nervous system: a SEER database analysis.

Authors:  Fujun Liu; Yuan Tian; Liangxue Zhou
Journal:  Neurosurg Rev       Date:  2021-01-08       Impact factor: 3.042

2.  Pulmonary and pleural metastasis of intracranial anaplastic meningioma in a 3-year-old boy: A case report.

Authors:  Yuko Honda; Rie Shirayama; Hiromi Morita; Koichi Kusuhara
Journal:  Mol Clin Oncol       Date:  2017-08-14

3.  Expression of RACGAP1 in high grade meningiomas: a potential role in cancer progression.

Authors:  Hong-Lin Ke; Rong-Hu Ke; Shi-Ting Li; Bin Li; Hai-Tao Lu; Xiao-Qiang Wang
Journal:  J Neurooncol       Date:  2013-03-25       Impact factor: 4.130

4.  Clinical features and long-term outcomes of pediatric intraventricular meningiomas: data from a single neurosurgical center.

Authors:  Zhicen Li; Hao Li; Yuming Jiao; Ji Ma; Shuo Wang; Yong Cao; Jizong Zhao
Journal:  Neurosurg Rev       Date:  2017-08-02       Impact factor: 3.042

5.  Morbidity in survivors of child and adolescent meningioma.

Authors:  Rishi S Kotecha; Peter Jacoby; Catherine H Cole; Nicholas G Gottardo
Journal:  Cancer       Date:  2013-09-19       Impact factor: 6.860

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.